Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer

C. Bottalico, V. Lorusso, M. Brandi, G. Micelli, C. Rella, M. Coviello, A. M. Atlante, M. Quaranta, M. De Lena

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lonidamine is an energolytic derivative of indazolcarboxilic acid which has been demonstrated to enhance cisplatin activity in ovarian cancer cell lines either sensitive or resistent to this drug, thus suggesting the potential reverting activity of the mechanisms of drug resistance. A study was performed on nine patients with advanced ovarian cancer treated with lonidamine (LND) plus cisplatin (CDDP) as salvage therapy after the failure of first-line platinum containing chemotherapy. Serum LND was determined with a high-performance liquid chromatography (HPLC) method. The objective clinical response included one complete and three partial responses (overall response 44%). High LND serum levels were observed in three of four responding patients. The serum LND concentrations for these patients, detected one hour after the first and second dose administrations, were 15.2 ± 1.1 and 14.6 ± 1.4 μg/ml, respectively. Toxicity was mild to moderate, except for myalgia. The high serum levels of lonidamine detected in three of four responding patients suggests that the synergism between LND and CDDP observed ovarian cancer cell lines may be confirmed in clinical practice. However, the potential role of LND in enhancing CDDP activity can be definitely established in large randomized trials.

Original languageEnglish
Pages (from-to)3865-3869
Number of pages5
JournalAnticancer Research
Volume16
Issue number6 B
Publication statusPublished - 1996

Fingerprint

Ovarian Neoplasms
High Pressure Liquid Chromatography
Serum
Cisplatin
Cell Line
Salvage Therapy
lonidamine
Myalgia
Platinum
Drug Resistance
Drug Therapy
Acids
Pharmaceutical Preparations

Keywords

  • Advanced ovarian cancer
  • Drug resistance
  • Lonidamine
  • Reversed-phase liquid chromatography

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bottalico, C., Lorusso, V., Brandi, M., Micelli, G., Rella, C., Coviello, M., ... De Lena, M. (1996). Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. Anticancer Research, 16(6 B), 3865-3869.

Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. / Bottalico, C.; Lorusso, V.; Brandi, M.; Micelli, G.; Rella, C.; Coviello, M.; Atlante, A. M.; Quaranta, M.; De Lena, M.

In: Anticancer Research, Vol. 16, No. 6 B, 1996, p. 3865-3869.

Research output: Contribution to journalArticle

Bottalico, C, Lorusso, V, Brandi, M, Micelli, G, Rella, C, Coviello, M, Atlante, AM, Quaranta, M & De Lena, M 1996, 'Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer', Anticancer Research, vol. 16, no. 6 B, pp. 3865-3869.
Bottalico, C. ; Lorusso, V. ; Brandi, M. ; Micelli, G. ; Rella, C. ; Coviello, M. ; Atlante, A. M. ; Quaranta, M. ; De Lena, M. / Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer. In: Anticancer Research. 1996 ; Vol. 16, No. 6 B. pp. 3865-3869.
@article{48c257039fa845598dd17bafd013dcdb,
title = "Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer",
abstract = "Lonidamine is an energolytic derivative of indazolcarboxilic acid which has been demonstrated to enhance cisplatin activity in ovarian cancer cell lines either sensitive or resistent to this drug, thus suggesting the potential reverting activity of the mechanisms of drug resistance. A study was performed on nine patients with advanced ovarian cancer treated with lonidamine (LND) plus cisplatin (CDDP) as salvage therapy after the failure of first-line platinum containing chemotherapy. Serum LND was determined with a high-performance liquid chromatography (HPLC) method. The objective clinical response included one complete and three partial responses (overall response 44{\%}). High LND serum levels were observed in three of four responding patients. The serum LND concentrations for these patients, detected one hour after the first and second dose administrations, were 15.2 ± 1.1 and 14.6 ± 1.4 μg/ml, respectively. Toxicity was mild to moderate, except for myalgia. The high serum levels of lonidamine detected in three of four responding patients suggests that the synergism between LND and CDDP observed ovarian cancer cell lines may be confirmed in clinical practice. However, the potential role of LND in enhancing CDDP activity can be definitely established in large randomized trials.",
keywords = "Advanced ovarian cancer, Drug resistance, Lonidamine, Reversed-phase liquid chromatography",
author = "C. Bottalico and V. Lorusso and M. Brandi and G. Micelli and C. Rella and M. Coviello and Atlante, {A. M.} and M. Quaranta and {De Lena}, M.",
year = "1996",
language = "English",
volume = "16",
pages = "3865--3869",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6 B",

}

TY - JOUR

T1 - Correlation between HPLC-determined lonidamine serum levels and clinical response in patients with advanced ovarian cancer

AU - Bottalico, C.

AU - Lorusso, V.

AU - Brandi, M.

AU - Micelli, G.

AU - Rella, C.

AU - Coviello, M.

AU - Atlante, A. M.

AU - Quaranta, M.

AU - De Lena, M.

PY - 1996

Y1 - 1996

N2 - Lonidamine is an energolytic derivative of indazolcarboxilic acid which has been demonstrated to enhance cisplatin activity in ovarian cancer cell lines either sensitive or resistent to this drug, thus suggesting the potential reverting activity of the mechanisms of drug resistance. A study was performed on nine patients with advanced ovarian cancer treated with lonidamine (LND) plus cisplatin (CDDP) as salvage therapy after the failure of first-line platinum containing chemotherapy. Serum LND was determined with a high-performance liquid chromatography (HPLC) method. The objective clinical response included one complete and three partial responses (overall response 44%). High LND serum levels were observed in three of four responding patients. The serum LND concentrations for these patients, detected one hour after the first and second dose administrations, were 15.2 ± 1.1 and 14.6 ± 1.4 μg/ml, respectively. Toxicity was mild to moderate, except for myalgia. The high serum levels of lonidamine detected in three of four responding patients suggests that the synergism between LND and CDDP observed ovarian cancer cell lines may be confirmed in clinical practice. However, the potential role of LND in enhancing CDDP activity can be definitely established in large randomized trials.

AB - Lonidamine is an energolytic derivative of indazolcarboxilic acid which has been demonstrated to enhance cisplatin activity in ovarian cancer cell lines either sensitive or resistent to this drug, thus suggesting the potential reverting activity of the mechanisms of drug resistance. A study was performed on nine patients with advanced ovarian cancer treated with lonidamine (LND) plus cisplatin (CDDP) as salvage therapy after the failure of first-line platinum containing chemotherapy. Serum LND was determined with a high-performance liquid chromatography (HPLC) method. The objective clinical response included one complete and three partial responses (overall response 44%). High LND serum levels were observed in three of four responding patients. The serum LND concentrations for these patients, detected one hour after the first and second dose administrations, were 15.2 ± 1.1 and 14.6 ± 1.4 μg/ml, respectively. Toxicity was mild to moderate, except for myalgia. The high serum levels of lonidamine detected in three of four responding patients suggests that the synergism between LND and CDDP observed ovarian cancer cell lines may be confirmed in clinical practice. However, the potential role of LND in enhancing CDDP activity can be definitely established in large randomized trials.

KW - Advanced ovarian cancer

KW - Drug resistance

KW - Lonidamine

KW - Reversed-phase liquid chromatography

UR - http://www.scopus.com/inward/record.url?scp=0030499482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030499482&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 3865

EP - 3869

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6 B

ER -